Bedside trial of COVID-19 ICU patients sees hydrocortisone improve recovery – Mirage News

• Researchers have found that intravenous hydrocortisone improves recovery and survival for critically ill COVID-19 patients.
• The finding comes as a result of the REMAP-CAP trial that was set up by a group of intensive care specialists from around the world to future-proof for pandemics like COVID-19.
• COVID-19 patients from more than 200 intensive care units around the world have been part of this adaptive randomised trial.

A global study, led from Mo…

Click here to view the original article.